Research progress on pathogenesis of rheumatoid arthritis combined with interstitial lung disease
LI Hui1 GAO Huiying2
1.The Second Clinical Medical College, Shanxi Medical University, Shanxi Province, Taiyuan 030001, China; 2.Department of Rheumatology and Immunology, the Second Hospital of Shanxi Medical University, Shanxi Province, Taiyuan 030001, China
Abstract：Rheumatoid arthritis combined with interstitial lung disease has a high incidence and mortality. Clinical research on its pathogenesis is of great significance, which can provide evidence for the targeted treatment of the disease, effectively control the disease early, improve the quality of life of patients, and reduce the mortality. In addition, research on the risk factors involve in the disease can provide evidence for the prevention of high-risk groups, early prevention, and diagnosis. It is of great significance to improve the prognosis of the disease. This paper mainly reviewes the environmental level of smoking population susceptibility, microbial pathogens, gene level of genetic susceptibility, gene variation, and molecular level of autoantibodies, immune cells and cytokines, and elaborated on the pathogenesis of various factors involved in rheumatoid arthritis complicated with interstitial lung disease.
[1] Dinache G，Popescu CC，Mogo?鬤an C，et al. Lung Damage in Rheumatoid Arthritis-A Retrospective Study [J]. Int J Mol Sci，2022，24（1）：28. [2] Bendstrup E，M?ller J，Kronborg-White S，et al. Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians [J]. J Clin Med，2019，8（12）：2038. [3] Khan T，Jose RJ，Renzoni EA，et al. A Closer Look at the Role of Anti-CCP Antibodies in the Pathogenesis of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Bronc- hiectasis [J]. Rheumatol Ther，2021，8（4）：1463-1475. [4] Kadura S，Raghu G. Rheumatoid arthritis-interstitial lung disease：manifestations and current concepts in pathogenesis and management [J]. Eur Respir Rev，2021，30（160）：210011. [5] McDermott GC，Doyle TJ，Sparks JA. Interstitial lung disease throughout the rheumatoid arthritis disease course [J]. Curr Opin Rheumatol，2021，33（3）：284-291. [6] Lou Y，Wei Q，Fan B，et al. The composition of the lung microbiome differs between patients with dermatomyositis and rheumatoid arthritis associated with interstitial lung disease [J]. Febs Open Bio，2022，12（1）：258-269. [7] Manfredi A，Luppi F，Cassone G，et al. Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia [J]. Expert Rev Clin Immu，2020，16（8）：751-770. [8] Dai Y，Wang W，Yu Y，et al. Rheumatoid arthritis-associated interstitial lung disease：an overview of epidemiology，pathogenesis and management [J]. Clin Rheumatol，2021，40（4）：1211-1220. [9] J?觟nsson E，Ljung L，Norrman E，et al. Pulmonary fibrosis in relation to genetic loci in an inception cohort of patients with early rheumatoid arthritis from northern Sweden [J]. Rheumatology（Oxford），2022，61（3）：943-952. [10] Helling BA，Gerber AN，Kadiyala V，et al. Regulation of MUC5B Expression in Idiopathic Pulmonary Fibrosis [J]. Am J Resp Cell Mol，2017，57（1）：91-99. [11] Florescu A，Gherghina FL，Mu?鬤etescu AE，et al. Novel Bio- markers，Diagnostic and Therapeutic Approach in Rheum- atoid Arthritis Interstitial Lung Disease——A Narrative Review [J]. Biomedicines，2022，10（6）：1367. [12] Konigsberg IR，Borie R，Walts AD，et al. Molecular Signatures of Idiopathic Pulmonary Fibrosis [J]. Am J Resp Cell Mol，2021，65（4）：430-441. [13] Shuai Z，Zheng S，Wang K，et al. Reestablish immune tolerance in rheumatoid arthritis [J]. Front Immunol，2022， 13：1012868. [14] Lai N，Jia W，Wang X，et al. Risk Factors and Changes of Peripheral NK and T Cells in Pulmonary Interstitial Fibrosis of Patients with Rheumatoid Arthritis [J]. Can Respir J，2019，2019：7262065. [15] Spagnolo P，Tonelli R，Samarelli AV，et al. The role of immune response in the pathogenesis of idiopathic pulmonary fibrosis：far beyond the Th1/Th2 imbalance [J]. Expert Opin Ther Tar，2022，26（7）：617-631. [16] Kokubo K，Onodera A，Kiuchi M，et al. Conventional and pathogenic Th2 cells in inflammation，tissue repair，and fibrosis [J]. Front Immunol，2022，13：945063. [17] Zhang J，Wang D，Wang L，et al. Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease [J]. Am J Physiol Lung Cell Mol Physiol，2019， 316（3）：L487-L497. [18] Okuno D，Sakamoto N，Akiyama Y，et al. Two Distinct Mec- hanisms Underlying γδT Cell-Mediated Regulation of Collagen Type I in Lung Fibroblasts [J]. Cells，2022，11（18）： 2816. [19] Shenderov K，Collins SL，Powell JD，et al. Immune dysregulation as a driver of idiopathic pulmonary fibrosis [J]. J Clin Invest，2021，131（2）：e143226. [20] 孙晴波，林炳静，徐寒梅，等. 肺纤维化的发病机制及其治疗药物研究进展[J].药学进展，2018，42（11）：868-873. [21] Raphael I，Nalawade S，Eagar TN，et al. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases [J]. Cytokine，2015，74（1）：5-17. [22] Desai O，Winkler J，Minasyan M，et al. The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis [J]. Front Med（Lausanne），2018，5：43. [23] Seyran M，Melanie S，Philip S，et al. Allies or enemies？The effect of regulatory T cells and related T lymphocytes on the profibrotic environment in bleomycin-injured lung mouse models [J]. Clin Exp Med，2022：1-14. [24] Thomas R，Qiao S，Yang X. Th17/Treg Imbalance：Implications in Lung Inflammatory Diseases [J]. Int J Mol Sci，2023， 24（5）：4865. [25] 王在强，傅恩清.调节性T细胞在肺纤维化中作用的研究进展[J].中华肺部疾病杂志（电子版），2019，12（2）：237-240. [26] Heukels P，Moor CC，von der Thüsen JH，et al. Inflammation and immunity in IPF pathogenesis and treatment [J]. Respir Med，2019：147，79-91. [27] Akiyama M，Kaneko Y. Pathogenesis，clinical features，and treatment strategy for rheumatoid arthritis-associated interstitial lung disease [J]. Autoimmun Rev，2022，21（5）：103056. [28] De Zorzi E，Spagnolo P，Cocconcelli E，et al. Thoracic Invol- vement in Systemic Autoimmune Rheumatic Diseases：Path- ogenesis and Management [J]. Clin Rev Allerg Immu，2022， 63（3）：472-489. [29] Lucchino B，Di Paolo M，Gioia C，et al. Identification of Subclinical Lung Involvement in ACPA-Positive Subjects through Functional Assessment and Serum Biomarkers [J]. Int J Mol Sci，2020，21（14）：5162. [30] Alunno A，Bistoni O，Pratesi F，et al. Association between anti-citrullinated alpha enolase antibodies and clinical features in a cohort of patients with rheumatoid arthritis：a pilot study [J]. Reumatismo，2018，70（2）：67-71. [31] Chen J，Song S，Liu Y，et al. Autoreactive T cells to citrullinated HSP90 are associated with interstitial lung disease in rheumatoid arthritis [J]. Int J Rheum Dis，2018，21（7）：1398-1405. [32] Castellanos-Moreira R，Rodríguez-García SC，Gomara MJ，et al. Anti-carbamylated proteins antibody repertoire in rheu- matoid arthritis：evidence of a new autoantibody linked to interstitial lung disease [J]. Ann Rheum Dis，2020，79（5）： 587-594.
2023, Vol. 20 
京公网安备 11010502046598号